BE1014078A6 - Composition a base de cefuroxime axetil et son utilisation. - Google Patents

Composition a base de cefuroxime axetil et son utilisation. Download PDF

Info

Publication number
BE1014078A6
BE1014078A6 BE2002/0667A BE200200667A BE1014078A6 BE 1014078 A6 BE1014078 A6 BE 1014078A6 BE 2002/0667 A BE2002/0667 A BE 2002/0667A BE 200200667 A BE200200667 A BE 200200667A BE 1014078 A6 BE1014078 A6 BE 1014078A6
Authority
BE
Belgium
Prior art keywords
cefuroxime axetil
composition based
composition
constitutive
lipids
Prior art date
Application number
BE2002/0667A
Other languages
English (en)
Inventor
Mathilde Ibanez Fernandez
Emilio Sanz Garriz
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1014078A6 publication Critical patent/BE1014078A6/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)

Abstract

Composition comprenant du céfuroxime axétil sous forme particulaire, les particules étant enrobées d'enrobages constitutifs d'un lipide ou mélange de lipides qui sont insolubles dans l'eau, la composition comprenant de plus un système d'édulcorant et un modificateur de texture qui servent à masquer le goût amer du céfuroxime axétil lors de l'administration orale.
BE2002/0667A 2001-11-23 2002-11-21 Composition a base de cefuroxime axetil et son utilisation. BE1014078A6 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23

Publications (1)

Publication Number Publication Date
BE1014078A6 true BE1014078A6 (fr) 2003-03-04

Family

ID=8183502

Family Applications (2)

Application Number Title Priority Date Filing Date
BE2002/0668A BE1015217A5 (fr) 2001-11-23 2002-11-21
BE2002/0667A BE1014078A6 (fr) 2001-11-23 2002-11-21 Composition a base de cefuroxime axetil et son utilisation.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE2002/0668A BE1015217A5 (fr) 2001-11-23 2002-11-21

Country Status (34)

Country Link
US (1) US20030161888A1 (fr)
EP (1) EP1446126B1 (fr)
JP (1) JP3497503B2 (fr)
KR (1) KR100979328B1 (fr)
CN (1) CN1297274C (fr)
AT (1) ATE473006T1 (fr)
AU (2) AU2002302147B2 (fr)
BE (2) BE1015217A5 (fr)
BR (1) BR0204767A (fr)
CA (1) CA2408198C (fr)
CH (1) CH693982A5 (fr)
CO (1) CO5580783A2 (fr)
CY (1) CY1110778T1 (fr)
CZ (1) CZ12993U1 (fr)
DE (3) DE60236952D1 (fr)
DK (1) DK1446126T3 (fr)
ES (2) ES2201932B2 (fr)
FR (1) FR2832635B1 (fr)
GB (1) GB2383536B (fr)
GR (1) GR1004522B (fr)
HR (2) HRP20020924A2 (fr)
HU (1) HUP0204026A3 (fr)
IL (2) IL161972A0 (fr)
IT (1) ITMI20022470A1 (fr)
MX (1) MXPA02011561A (fr)
NO (1) NO335273B1 (fr)
NZ (1) NZ533092A (fr)
PL (1) PL205325B1 (fr)
PT (1) PT1446126E (fr)
RU (1) RU2241460C2 (fr)
SI (1) SI1446126T1 (fr)
TR (1) TR200202559A2 (fr)
WO (1) WO2003043638A1 (fr)
ZA (1) ZA200209473B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) * 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
ES2668203T3 (es) 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
WO2011085181A1 (fr) * 2010-01-08 2011-07-14 Eurand, Inc. Composition de topiramate à goût masqué et comprimé à délitement oral l'incluant
WO2011139254A2 (fr) 2010-05-04 2011-11-10 Mahmut Bilgic Formulations pharmaceutiques comprenant du céfuroxime axétil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
EP2741750A1 (fr) * 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Composition pharmaceutique comprenant du céfuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
WO2013066616A1 (fr) 2011-10-31 2013-05-10 Glaxo Wellcome Manufacturing Pte Ltd Formulation de pazopanib
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
CA1094545A (fr) * 1976-02-16 1981-01-27 Michael Gregson Traduction non-disponible
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
AU5681294A (en) * 1992-11-30 1994-06-22 Kv Pharmaceutical Company Tastemasked pharmaceutical materials
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
ES2565163T3 (es) * 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
CA2209868C (fr) * 1997-08-15 2001-08-14 Bernard Charles Sherman Compositions pharmaceutiques a base de cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
AU2002302147B2 (en) 2005-01-20
DE20218068U1 (de) 2003-03-27
PL205325B1 (pl) 2010-04-30
RU2241460C2 (ru) 2004-12-10
JP3497503B2 (ja) 2004-02-16
CH693982A5 (de) 2004-05-28
BR0204767A (pt) 2003-09-16
HUP0204026A2 (hu) 2003-08-28
EP1446126A1 (fr) 2004-08-18
JP2003160493A (ja) 2003-06-03
CO5580783A2 (es) 2005-11-30
IL161972A (en) 2009-06-15
AU2002338950A1 (en) 2003-06-10
HRP20020924A2 (en) 2003-10-31
CA2408198A1 (fr) 2003-02-02
CN1421206A (zh) 2003-06-04
CZ12993U1 (cs) 2003-02-10
CY1110778T1 (el) 2015-06-10
ATE473006T1 (de) 2010-07-15
GB0227215D0 (en) 2002-12-24
GB2383536A (en) 2003-07-02
NZ533092A (en) 2006-02-24
NO20042620L (no) 2004-06-22
PL357259A1 (en) 2003-06-02
GR1004522B (el) 2004-04-06
CA2408198C (fr) 2004-03-09
PT1446126E (pt) 2010-09-24
ITMI20022470A1 (it) 2003-05-24
DE10254412A1 (de) 2003-06-12
KR100979328B1 (ko) 2010-08-31
US20030161888A1 (en) 2003-08-28
WO2003043638A1 (fr) 2003-05-30
ES2201932B2 (es) 2005-03-16
EP1446126B1 (fr) 2010-07-07
KR20050044590A (ko) 2005-05-12
IL161972A0 (en) 2005-11-20
HU0204026D0 (en) 2003-01-28
MXPA02011561A (es) 2005-07-13
SI1446126T1 (sl) 2010-10-29
BE1015217A5 (fr) 2004-11-09
NO335273B1 (no) 2014-11-03
HRP20020923A2 (en) 2003-10-31
ES2347536T3 (es) 2010-11-02
TR200202559A2 (tr) 2003-06-23
FR2832635A1 (fr) 2003-05-30
CN1297274C (zh) 2007-01-31
DE60236952D1 (de) 2010-08-19
GR20020100506A (el) 2003-07-16
ZA200209473B (en) 2003-06-10
GB2383536B (en) 2003-11-19
ES2201932A1 (es) 2004-03-16
HUP0204026A3 (en) 2004-09-28
FR2832635B1 (fr) 2006-04-21
DK1446126T3 (da) 2010-10-11

Similar Documents

Publication Publication Date Title
BE1014078A6 (fr) Composition a base de cefuroxime axetil et son utilisation.
FR2576774B1 (fr) Dispositif de positionnement tridimensionnel de deux pieces quelconques, en particulier de deux parties d'os, et permettant de modifier ledit positionnement
ES2062417T3 (es) Composiciones farmaceuticas de cimetidina.
HK1035142A1 (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
ID28003A (id) Turunan-turunan adamantana
CA2103829A1 (fr) Conjugues peg-interferon
PT999843E (pt) Composicoes farmaceuticas contendo vitamina d e calcio, sua preparacao e uso terapeutico
BR0213379A (pt) Formulação resistente a derramamento de mascaramento de gosto
ES2140489T3 (es) Receptor de interferona soluble, su preparacion y su uso.
FI960507A (fi) Uudelleendispergoituvia, jauhemaisia ydinkuoripolymeerejä, niiden valmistus ja käyttö
AU5591296A (en) N-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl)benzamide derivatives, their preparation and their application in therapeutics
EP1431391A3 (fr) Rantes mute et son utilisation thérapeutique
FR2684848B1 (fr) Utilisation du glucomannane pour la preparation d'une gelee orale a effet de satiete et gelee orale comprenant du glucomannane a effet de satiete ainsi obtenue.
FR2768731B1 (fr) Derives insatures en position -4 du 6-tert-butyl-1,1- dimethylindane et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique
IL122759A (en) METHOD OF DETERMINING THE DEGREE OF AGGREGATION OF THE betaA4 PEPTIDE
ITRM910522A1 (it) Procedimento per la preparazione di un preparato cosmetico e/o farmaceutico in forma di pellicola spugnosa idrosolubile, e pellicola spugnosa idrosolubile cosi' ottenibile
Jagielski The effect of counselling and enjoyment on exercise adherence
ITMI20011670A0 (it) Uso dell'r(-)flurbiprofen nella preparazione di un medicamento antipiretico
JPS5748904A (en) Transparent cosmetic
Yim et al. The Effects of Dietary Counceling and Drug Treatment of the Serum Lipid Levels in Hyperlipidemic Patients
ITMI20001825A1 (it) Uso dell'r(-) flurbiprofen nella preparazione di un medicamento antipiretico
EP0579130A3 (fr) Des protéines fonctionalisées et leur utilisation pour la préparation de composés conjugués marqués.
ITVA960020A0 (it) Antiartrosico ed osteoporotico invenzione sull'uso ed la somministrazione dietetica farmaceutica di
ITTO950286A0 (it) Uso dell'incenso in campo agronomico.
Sakamoto Ruth Towse (ed.), Baumol's Cost Disease: The Arts and other Victims, Edward Elgar Publishing, Inc., 1997

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *GLAXO GROUP LTD

Effective date: 20081121